CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 14:08:09 24/05/2024 BST | ||
| 2.14 EUR | -17.37% |
|
| Current month | +25.12% | ||
| 1 month | +20.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 2.14 | -17.37% |
| 23/05/24 | 2.59 | +23.33% |
| 22/05/24 | 2.1 | -4.55% |
| 21/05/24 | 2.2 | +33.74% |
| 17/05/24 | 1.645 | -15.42% |
Real-time Euronext Paris
Last update May 24, 2024 at 02:08 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WH9LB | |
| ISIN | NLBNPNL2HAS7 |
| Date issued | 24/08/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.03 € |
|---|---|
| Lowest since issue | 0.215 € |
| Spread | 0.06 € |
| Spread % | 2.79% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
937.4
DKK
Average target price
909.2
DKK
Spread / Average Target
-3.00%
- Stock Market
- Certificates
- WH9LB Certificat
